Therapy Areas: AIDS & HIV
ViiV Healthcare reveals data from phase III TANGO study
26 July 2019 -

ViiV Healthcare, a specialist HIV company majority owned by GSK, along with Pfizer Inc and Shionogi Limited as shareholders has revealed data from its phase III TANGO study for treatment of HIV, it was reported yesterday.

The study revealed that a 2-drug regimen of Dovato (dolutegravir/lamivudine) has similar efficacy to a tenofovir alafenamide fumarate-containing regimen of around three drugs in virally supressed and stable adults with HIV-1.

The study was conducted to evaluate if adults living with HIV-1 who had maintained viral suppression for around six months on a TAF-containing regimen of around three drugs, were able to maintain similar rates of viral suppression after switching to the 2DR of dolutegravir/lamivudine in a fixed-dose combination.

The study met its primary endpoint.

Kimberly Smith, MD, Head of Global Research & Medical Strategy at ViiV Healthcare, said, 'With HIV now considered a chronic condition and people living with HIV needing antiretroviral treatments for life, taking fewer medicines over a lifetime has become an important consideration for the community. The TANGO study was designed to answer the question, can a 2-drug regimen of dolutegravir/lamivudine maintain viral suppression as well as a TAF-containing regimen? We're delighted that the Week 48 results of the study confirm that it can. These data present evidence that a dolutegravir/lamivudine 2-drug regimen is as effective as a TAF-containing, 3-drug regimen for people living with HIV.'